Abstract
Purpose
Conditional survival (CS) offers more relevant prognostic information for patients once they have survived for some time. The objective of this study was to determine the CS for advanced renal cell carcinoma (RCC) patients treated with vascular endothelial growth factor-targeted therapy.
Methods
A total of 345 patients treated between 2006 and 2011 fulfilled the inclusion criteria and were reviewed for analyses. The 1-year conditional and actual survival rates were calculated for survivors from treatment to month 24. Subgroup-specific CS rates were generated after adjustment of the covariate influence. The Cox proportional hazard models were used to assess the prognostic factors at baseline and 1-year landmark.
Results
The probabilities of surviving an additional year given survival to 6, 12, 18, and 24 months were 72.2, 76.3, 78.2, and 78.6 %, respectively. Remarkable increase in CS was observed in patients initially classified as intermediate or poor risk according to Heng risk groups. For patients survived 24 months after treatment, the adjusted CS for the following year was over 80 % regardless of initial risk attribution. Compared to baseline analysis, Heng risk groups were less predictive of survivorship after surviving 1 year. The addition of disease control status to multifactorial model significantly improved survival estimation for 1-year survivors (p < 0.01).
Conclusions
CS provides useful information regarding life expectancy for survivors of advanced RCC treated with targeted therapy. Furthermore, disease control status within a specific period of time is critical to the prediction of subsequent survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albiges L, Salem M, Rini B, Escudier B (2011) Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin N Am 25(4):813–833. doi:10.1016/j.hoc.2011.04.006
Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1(11):710–719
Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA (2009) Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol 27(35):5938–5943. doi:10.1200/JCO.2009.23.1860
Coate LE, John T, Tsao MS, Shepherd FA (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10(10):1001–1010. doi:10.1016/S1470-2045(09)70155-X
Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23):2477–2490. doi:10.1056/NEJMra043172
Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387. doi:10.1002/(SICI)1097-0258(19960229)15:4<361:AID-SIM168>3.0.CO;2-4
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. doi:10.1200/JCO.2008.21.4809
Heng DY, Xie W, Harshman LC, Bjarnason GA, Vaishampayan UN, Lebert J, Wood L, Donskov F, Tan M, Rha SY, Wells C, Wang Y, Kollmannsberger C, Rini BI, Choueiri TK, Consortium ImD (2011) External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy. Paper presented at the 2011 ASCO Annual Meeting
Henson DE, Ries LA (1994) On the estimation of survival. Semin Surg Oncol 10(1):2–6
Janssen-Heijnen ML, Gondos A, Bray F, Hakulinen T, Brewster DH, Brenner H, Coebergh JW (2010) Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol 28(15):2520–2528. doi:10.1200/JCO.2009.25.9697
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107
Kato I, Severson RK, Schwartz AG (2001) Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer 92(8):2211–2219
Linehan WM, Zbar B (2004) Focus on kidney cancer. Cancer Cell 6(3):223–228. doi:10.1016/j.ccr.2004.09.006
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. doi:10.1200/JCO.2008.20.1293
Naito S, Tomita Y, Rha SY, Uemura H, Oya M, Song HZ, Zhong LH, Wahid MI (2010) Kidney cancer working group report. Jpn J Clin Oncol 40(Suppl 1):i51–i56. doi:10.1093/jjco/hyq127
Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M (2011) Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol 29(31):4175–4180. doi:10.1200/JCO.2010.32.4343
Sarkar D (2008) Lattice: Multivariate Data Visualization with R. Use R!, 1st edn. Springer, New York
Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI (2011) Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 59(1):135–141. doi:10.1016/j.eururo.2010.10.029
R Development Core Team (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/
Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR Jr, O’Connell MJ, Wolmark N, Wang SJ (2010) Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol 28(15):2544–2548. doi:10.1200/JCO.2009.23.0573
Acknowledgments
This work was supported by National Natural Science Foundation of China (grant number 81001131).
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Y. Zhu and Y. P. Hong have been contributed equally to this work.
Rights and permissions
About this article
Cite this article
Zhu, Y., Hong, Y.P., Zhang, H.L. et al. Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma. J Cancer Res Clin Oncol 138, 1901–1907 (2012). https://doi.org/10.1007/s00432-012-1266-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-012-1266-3